🟢 Tiziana Life Sciences is trading 7.6% up in after-hours trading after completing Alzheimer’s trial enrollment

Tiziana Life Sciences is trading at $1.13, up 7.62%, in after-hours trading; a clinical-trial milestone may have supported the gain.

• The company announced October 16 that the last patient began dosing in its Phase 2 intranasal foralumab trial for early/mild Alzheimer’s disease, completing enrollment.
• Topline data are expected in Q1 2027. Broader markets were weak, so the move was not aligned with the overall market’s direction.